Theratechnologies Receives FDA Approval Of Prior Approval Supplement (Pas) For Egrifta Sv® Sbla
April 8 (Reuters) - Theratechnologies Inc TH.TO:
THERATECHNOLOGIES RECEIVES FDA APPROVAL OF PRIOR APPROVAL SUPPLEMENT (PAS) FOR EGRIFTA SV® SBLA
THERATECHNOLOGIES: FDA ACTION ALLOWS FOR UNRESTRICTED DISTRIBUTION OF EGRIFTA SV, REMOVING UNCERTAINTY ABOUT ALL MANUFACTURED BATCHES
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

Anthropic Eclipses OpenAI in Secondary Market as Valuation Hits $1 Trillion Milestone, Is the AI Market Overheating Now?

Robinhood Stock Predictions: Can HOOD Reach the $1,000 Milestone?

Tesla Officially Announces. Third-Generation Humanoid Robot to Debut Mid-Year, Mass Production to Start in Third Quarter

Intel Better-Than-Expected Earnings Released, Stock Surges 20% After-Hours, AI Computing Power Enters CPU Moment?

Tradingkey








